Cardiovascular risk in rheumatoid arthritis

Joint Bone Spine

Volumn 81, Issue 4, 2014, Pages 298-302

  Soubrier, Martin ^a   Chamoux, Nicolas Barber ^b   Tatar, Zuzana ^a   Couderc, Marion ^a   Dubost, Jean Jacques ^a   Mathieu, Sylvain ^a  

^a Service de Rhumatologie   (France)

^b Service de Cardiologie   (France)

Author keywords

Cardiovascular risk; Dyslipidemia; Glucocorticoid therapy; NSAID; Rheumatoid arthritis; Risk equation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROMA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIET; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DYSLIPIDEMIA; EXERCISE; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; LIPID OXIDATION; META ANALYSIS (TOPIC); OBESITY; PATHOPHYSIOLOGY; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK MANAGEMENT; SECONDARY PREVENTION; SHORT SURVEY; SMOKING; SMOKING CESSATION; WEIGHT REDUCTION; ARTERY COMPLIANCE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DISEASE DURATION; ECHOGRAPHY; FOLLOW UP; GENETIC SUSCEPTIBILITY; MORBIDITY; POPULATION; PREDICTION; RISK FACTOR;

CARDIOVASCULAR RISK; DYSLIPIDEMIA; GLUCOCORTICOID THERAPY; NSAID; RHEUMATOID ARTHRITIS; RISK EQUATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 84904104223     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.01.009     Document Type: Short Survey

References (59)

1. Dadoun S., Zeboulon-Ktorza N., Combescure C., et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013, 80:29-33.
2. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697.
3. Kerola A.M., Kauppi M.J., Kerola T., et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012, 71:1606-1615.
4. Symmons D.P., Gabriel S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011, 7:399-408.
5. van Halm V.P., Peters M.J., Voskuyl A.E., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross-sectional study. Ann Rheum Dis 2009, 68:1395-1400.
6. Lindhardsen J., Ahlehoff O., Gislason G.H., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011, 70:929-934.
7. Peters M.J., van Halm V.P., Voskuyl A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
8. Sandoo A., Veldhuijzen van Zanten J.J., Metsios G.S., et al. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2011, 50:2125-2139.
9. Polak J.F., Pencina M.J., Pencina K.M., et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011, 365:213-221.
10. van Sijl A.M., Peters M.J., Knol D.K., et al. Carotid intima-media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011, 40:389-397.
11. Wong B.W., Meredith A., Lin D., et al. The biological role of inflammation in atherosclerosis. Can J Cardiol 2012, 28:631-641.
12. Emerging Risk Factors Collaboration, Kaptoge S., Di Angelantonio E., et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012, 367:1310-1320.
13. Grad E., Danenberg H.D. C-reactive protein and atherothrombosis: cause or effect?. Blood Rev 2013, 27:23-29.
14. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
15. C-Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F., Gao P., et al. Association between C-reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011, 342:d548.
16. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N., Butterworth A.S., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205-1213.
17. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379:1214-1224.
18. Popa C.D., Arts E., Fransen J., et al. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012, 2012:785946.
19. Payet S., Pereira B., Soubrier M., et al. The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2012, 41:e4-e5.
20. Daïen C.I., Duny Y., Barnetche T., et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012, 71:862-868.
21. Mathieu S., Pereira B., Dubost J.J., et al. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 2012, 51:1107-1111.
22. Raterman H.G., Levels H., Voskuyl A.E., et al. HDL protein composition alters from pro-atherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013, 72:560-565.
23. Strang A.C., Bisoendial R.J., Kootte R.S., et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013, 229:174-181.
24. Navarro-Millán I., Charles-Schoeman C., Yang S., et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013, 65:1430-1438.
25. Morris S.J., Wasko M.C., Antohe J.L., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011, 63:530-534.
26. Boyer J.F., Gourraud P.A., Cantagrel A., et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011, 78:179-183.
27. Solomon D.H., Massarotti E., Garg R., et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
28. Wasko M.C., Hubert H.B., Lingala V.B., et al. Hydroxychloroquine risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298:187-193.
29. Wolfe F., Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:1471-1479.
30. Solomon D.H., Kremer J., Curtis J.R., et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010, 69:1920-1925.
31. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
32. Soubrier M., Rosenbaum D., Tatar Z., et al. Vascular effects of nonsteroidal anti-inflammatory drugs. Joint Bone Spine 2013, 80:358-362.
33. Coxib and traditional NSAID Trialists' (CNT) Collaboration Vascular and upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, 382:769-779.
34. Lindhardsen J., Gislason G.H., Jacobsen S., et al. Nonsteroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013, 10.1136/annrheumdis-2012-203137.
35. Ruyssen-Witrand A., Fautrel B., Saraux A., et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011, 78:23-30.
36. Aviña-Zubieta J.A., Abrahamowicz M., De Vera M.A., et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013, 52:68-75.
37. Provan S.A., Semb A.G., Hisdal J., et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011, 70:812-817.
38. Micha R., Imamura F., Wyler von Ballmoos M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108:1362-1370.
39. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011, 63:522-529.
40. Greenberg J.D., Kremer J.M., Curtis J.R., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.
41. Ljung L., Simard J.F., Jacobsson L., et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012, 64:42-52.
42. Mathieu S., Couderc M., Pereira B., et al. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: A meta-analysis. Semin Arthritis Rheum 2013, [pii: S0049-0172(13)00088-7].
43. Crowson C.S., Matteson E.L., Roger V.L., et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110:420-424.
44. Crowson C.S., Therneau T.M., Davis J.M., et al. Accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum 2013.
45. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:1-44.
46. Corrales A., González-Juanatey C., Peiró M.E., et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014, 73:722-727.
47. Corrales A., Parra J.A., González-Juanatey C., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013.
48. Agence française de sécurité sanitaire des produits de santé Prise en charge thérapeutique du patient dyslipidémique 2005, [In French, Fiches annales CNQ 08BIO1, 06/05/2011, http://www.afssaps.fr].
49. Pham T., Gossec L., Constantin A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:379-387.
50. Goëb V., Ardizzone M., Arnaud L., et al. Recommendations for using TNFα antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. Joint Bone Spine 2013, 80:574-581.
51. Stone N.J., Robinson J., Lichtenstein A.H., et al. Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice Guidelines. Circulation 2013, [Epub ahead of print]. 10.1161/01.circ.0000437738.63583.7a.
52. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
53. Sheng X., Murphy M.J., Macdonald T.M., et al. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012, 39:32-40.
54. Semb A.G., Holme I., Kvien T.K., et al. Intensive lipid-lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid-lowering (IDEAL) trial. Rheumatology (Oxford) 2011, 50:324-329.
55. De Vera M.A., Choi H., Abrahamowicz M., Kopec J., et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011, 70:1020-1024.
56. Soubrier M., Zerkak D., Dougados M. Indications for lowering LDL-cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 2006, 33:1766-1769.
57. Akkara Veetil B.M., Myasoedova E., Matteson E.L., et al. Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 2013, 40:1082-1088.
58. McCarey D., McInnes I., Madhok R., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double blind, randomized placebo-controlled trial. Lancet 2004, 363:2015-2021.
59. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.